Clinuvel Pharmaceuticals Ltd
ASX:CUV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Clinuvel Pharmaceuticals Ltd
Capital Expenditures
Clinuvel Pharmaceuticals Ltd
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Capital Expenditures
-AU$390.2k
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-44%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Capital Expenditures
-$1.1m
|
CAGR 3-Years
-70%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Capital Expenditures
-$1.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-9%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Capital Expenditures
-AU$56m
|
CAGR 3-Years
-84%
|
CAGR 5-Years
-181%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Capital Expenditures
-AU$463.8k
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-28%
|
|
Clinuvel Pharmaceuticals Ltd
Glance View
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). The company is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
See Also
What is Clinuvel Pharmaceuticals Ltd's Capital Expenditures?
Capital Expenditures
-390.2k
AUD
Based on the financial report for Dec 31, 2025, Clinuvel Pharmaceuticals Ltd's Capital Expenditures amounts to -390.2k AUD.
What is Clinuvel Pharmaceuticals Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-44%
Over the last year, the Capital Expenditures growth was -17%. The average annual Capital Expenditures growth rates for Clinuvel Pharmaceuticals Ltd have been 20% over the past three years , 23% over the past five years , and -44% over the past ten years .
